Phase 2 Cardiomyopathy Trial, Recruiting NCT06922994 Sponsor: Centro Cardiologico Monzino Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT06922994
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of signing the consent form
  • You have been diagnosed with Arrhythmogenic Cardiomyopathy (a specific heart condition) based on established medical criteria

Who may not be able to join:

  • You have a known allergy or sensitivity to atorvastatin (a cholesterol medication) or any of its ingredients
  • You have moderate or severe liver disease
  • You have a diagnosed muscle disease
  • Your heart's pumping strength (left ventricle) is below a certain level (confirm with trial site)
  • You have severe heart failure symptoms that significantly limit your daily activities (confirm with trial site)
  • You have another type of heart condition, such as a different cardiomyopathy, significant heart valve problems, high blood pressure in the lungs, or a heart defect present from birth
  • You have high cholesterol that requires treatment with cholesterol-lowering medication
  • You have had a heart transplant
  • Your expected life expectancy is less than 2 years
  • You have another medical condition that the study doctor believes makes participation unsafe or unreliable (confirm with trial site)
  • You are currently taking certain medications that can interact with the study drug, including some antibiotics (e.g., erythromycin, clarithromycin), antifungals, HIV medications, or certain others (confirm with trial site)
  • You are currently taking fusidic acid, an antibiotic used for bacterial infections
  • You are taking certain antiviral medications used to treat Hepatitis C (confirm with trial site)
  • You are currently taking any other cholesterol-lowering medications, including statins or similar drugs
  • You are taking medications primarily used as antioxidants
  • You have taken part in another clinical trial involving an experimental drug within the last 30 days (or longer, depending on the drug used)
  • You are pregnant or currently breastfeeding
  • You are a woman who could become pregnant and are not using adequate contraception
  • You have a known dependency on alcohol or drugs
  • You are unable to have a cardiac MRI scan (a special heart imaging test)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Claudio Tondo, Centro Cardiologico Monzino IRCCS

Phone: +39 0258002752

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Centro Cardiologico Monzino
Registry
ClinicalTrials.gov
Start date
31 March 2025
Est. completion
30 November 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Efficacy of Atorvastatin in avoiding functional right ventricular deterioration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov